Journal of Drug Discovery and Health Sciences, 2025;2(1):37-46 eISSN- 3048-8842

Journal of Drug Discovery and Health Sciences

journal home page : https://jddhs.com/index.php/jddhs/index

Review Article

Exploring the role of Probiotics, Prebiotics, and Symbiotics in the management of neurodegenerative disease

Amita Singh Yadav[1], Deepika Shukla[1], Ashutosh Yadav[2], Vipul Kumar Singh[1*], Yashpal S Kori[3]

[1]*Maharishi School of Pharmaceutical Sciences, MUIT, Lucknow, U.P., 226013, India.*
[2]*Institute of Pharmacy, Dr. Shakuntala Misra National Rehabilitation University, Lucknow, U.P., 226017, India.*
[3]*Kamla Nehru Institute of Management and Technology Faridipur, Sultanpur, U.P., 228118, India*

ARTICLE INFO

Article history:
Received: 12 January, 2025
Revised: 20 February, 2025
Accepted: 12 March, 2025
Published: 25 March, 2025

Keywords:
Gut Microbiota, Homeostasis, Microbiome, Neuroinflammation, Systemic inflammation, etc.

DOI:
10.21590/jddhs.02.01.06

ABSTRACT

The progressive nature of neurodegenerative disorders, including multiple sclerosis, Parkinson's, and Alzheimer's, poses major worldwide health issues with few available treatments. Recent research indicates that the gut microbiota is essential for controlling neuroinflammation and brain function, affecting the pathophysiology of many diseases. Probiotics, prebiotics, and symbiotics are investigated in this review as prospective innovative therapeutic approaches for treating neurodegenerative illnesses. Probiotics are microorganisms that help in boosting the host's health. They have demonstrated promise in altering the makeup of the gut microbiota, lowering systemic inflammation, and enhancing cognitive abilities. Prebiotics are indigestible dietary ingredients that promote the growth of beneficial bacteria. By encouraging the production of neuroprotective metabolites, prebiotics help to preserve the balance of the gut-brain axis. To optimize and restore the balance of the gut microbiota and produce neuroprotective benefits, symbiotics—a synergistic blend of probiotics and prebiotics—offer an integrated strategy. Recent preclinical and clinical investigations critically assess the processes by which these biotic therapies influence neuroinflammation, oxidative stress, and neurotrophic factors. Although initial results are encouraging, more thorough research is necessary to identify the best strains, doses, and delivery techniques before using these biotic-based treatments in clinical settings. Comprehending the unique microbiome profiles of individuals and their correlation with neurodegenerative disease pathways will also be essential for tailoring these treatment approaches. Overall, the field of probiotics, prebiotics, and symbiotics has great promise for treating neurodegenerative illnesses. These supplements may provide novel, non-invasive ways to treat patients and enhance their quality of life.

Introduction

Neurodegenerative disorders, which cause gradual loss of neuron structure and function, are a serious worldwide health concern. These illnesses, which include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis, not only drastically reduce the quality of life for people who suffer from them, but also create huge strains on global healthcare systems. The prevalence of these diseases is rising, particularly in aging populations, making the need for effective prevention and treatment strategies more urgent than ever *(Elandia, 2022)*. The gut-brain axis may have a role in the development of neurodegenerative illnesses, according the results of recent research. The vast system of reciprocal communication that links the central nervous system with the digestive tract is known as the gut-brain axis.

***Corresponding Author:** Vipul Kumar Singh

Address: Maharishi School of Pharmaceutical Sciences, MUIT, Lucknow, U.P., 226013, India.

Email ✉: beingvipulsingh@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

This link is mediated by several neurological, hormonal, and immunological pathways, all of which are highly influenced by the gut microbiota, a diverse collection of bacteria that dwell in the intestines. Understanding how the gut microbiota influences brain function is crucial for developing novel treatment techniques for neurodegenerative diseases. Research has increasingly shown that dysbiosis, an imbalance in the gut microbiota, can contribute to neuroinflammation and neuronal damage, potentially exacerbating the progression of neurodegenerative conditions *(Tian et al., 2022)*.

The purpose is to investigate increasing data relating gut microbiota to neurodegenerative disorders. We want to explain the fundamental processes of the gut-brain axis and its implications for neurodegeneration by reviewing the most recent research on this topic. This review will present a detailed overview of existing knowledge, highlight noteworthy results, and recommend future research possibilities. Finally, we hope to emphasize the role of the gut microbiota in neurodegenerative illness and argue for microbiome-focused tactics in the development of novel therapeutic approaches.

Probiotics in Neurodegenerative Diseases

As the discipline of neurogastroenterology develops, it has shown fascinating links between brain function and gut health, making probiotics a potentially effective treatment option for neurodegenerative illnesses. Probiotics are living microorganisms that enhance the health of the host when given in sufficient quantities. Their impacts on gastrointestinal health have been thoroughly studied. They could also be useful in regulating the gut-brain axis, a network of two-way communication between the gastrointestinal tract and the central nervous system, according to recent studies. This network is essential for preserving brain function, and the pathophysiology of neurodegenerative illnesses including multiple sclerosis, Parkinson's, and Alzheimer's is increasingly linked to its disturbance. By influencing gut microbiota composition and function, probiotics may offer novel strategies to mitigate neuroinflammation, enhance neuronal health, and ultimately slow the progression of these debilitating conditions (Kwon & Koh, 2020). As our knowledge of the gut-brain axis grows, probiotic usage in the treatment of neurodegenerative diseases shows promise for both clinical and research applications. Probiotics are living microorganisms that offer health benefits to the host when given in the right doses. These good bacteria, which are mostly present in fermented foods and dietary supplements, are essential for maintaining and reestablishing gut health.

Modulation of gut microbiota

Overall health depends on the gut microbiota's stability and variety, which probiotics improve. They prevent harmful bacterial colonization by competing with pathogenic bacteria for adhesion sites and nutrition *(Laver et al., 2016)*.

Anti-inflammatory effects

By altering the synthesis of anti-inflammatory cytokines and blocking pro-inflammatory pathways, probiotics can lower systemic inflammation by modifying immune responses *(Aizawa et al., 2016).*

Enhancement of gut barrier function

Toxins and dangerous germs cannot get into the circulation because they fortify the gut epithelial barrier.

Production of beneficial metabolites

Probiotics regulate brain function via the gut-brain axis by generating short-chain fatty acids (SCFAs) and other metabolites with systemic effects.

Animal Studies models of Alzheimer's disease using Probiotics

In recent years, there has been a notable surge in interest in researching probiotics as a potential therapy for Alzheimer's disease (AD), particularly when employing animal models. Transgenic mice and other animal models have long been used to study Alzheimer's disease, a crippling neurodegenerative illness marked by cognitive decline and memory loss, in order to evaluate prospective therapies and comprehend its biology *(Huang et al., 2016)*. The possibility that the gut bacteria contribute to dementia has led researchers to focus on the gut-brain axis, a two-way communication pathway between the central nervous system and the gastrointestinal tract. Live microbes that benefit the host's health are called probiotics. Their potential to alter the gut microbiota and, consequently, affect brain health is being studied. Studies using animal models have provided promising insights, demonstrating that probiotics may ameliorate symptoms of via improving cognitive performance, decreasing neuroinflammation, and changing the development of amyloid-beta plaque in Alzheimer's disease *(Hyde et al., 2013).* Novel microbiome-based therapies for Alzheimer's disease might be developed in this emerging sector, opening up new therapy and preventative options. Research on animals has demonstrated as shown in figure 1 that probiotics can benefit models of Alzheimer's disease (AD).

Reduction in amyloid plaques

Probiotic supplementation has been associated with a decrease in amyloid-beta plaques, a hallmark of AD, in the brains of affected mice.

Improved cognitive function

Probiotics have been shown to enhance memory and learning abilities in AD models, likely due to their anti-inflammatory effects and modulation of gut-brain axis signaling *(Rao et al., 2014)*.



Figure 1: Role of Gut Microbiota in Neuroinflammation and Neurodegeneration

Decreased neuroinflammation

Probiotics reduce markers of inflammation in the brain, which is crucial in mitigating the progression of AD.

Animal Studies models of Parkinson's disease using Probiotics

According to Burns and Iliffe (2009), Parkinson's disease (PD) is a progressive neurodegenerative illness that causes non-motor symptoms including gastrointestinal issues in addition to motor symptoms like bradykinesia, rigidity, and tremors. Parkinson's disease is characterized by the degeneration of dopaminergic neurons in the substantia nigra. A growing body of research indicates that gut microbiota and neurodegenerative processes are significantly linked, making the gut-brain axis an important field of study in paralysis. In order to better understand the pathogenesis of Parkinson's disease and investigate possible therapy approaches, animal models have proven invaluable. Probiotics' ability to alter gut microbiota and hence affect neuroinflammation and neurodegeneration has recently drawn attention to their application in these settings. This aims to synthesize current findings from animal studies on the use of probiotics in PD, highlighting their mechanisms of action, therapeutic benefits, and implications for future research *(World Health Organization [WHO], n.d.)*. By leveraging probiotic interventions in animal models, researchers can gain deeper insights into the gut-brain interactions in PD and pave the way for innovative treatment strategies that target the microbiome. Research on Parkinson's disease (PD) models has also highlighted the benefits of probiotics:

Motor function improvement

Probiotic treatment in PD models has been linked to improvements in motor function, reducing the severity of symptoms such as tremors and rigidity.

Protection of dopaminergic neurons

Probiotics have shown neuroprotective effects, helping to preserve the integrity and function of dopaminergic neurons, which are critically affected in PD.

Reduction in gut inflammation

Given the bidirectional relationship between the gut and brain, probiotics help in reducing gut inflammation, which is believed to contribute to the pathogenesis of PD.

Animal Studies models on others using Probiotics

Animal studies play a pivotal role in understanding the effects and mechanisms of probiotics on various health conditions. These models provide invaluable insights into the complex interactions between probiotics and host physiology, enabling researchers to explore their potential therapeutic applications. Scientists can explain the routes via which probiotics exert their therapeutic benefits by investigating their influence on animal models with illnesses such as inflammatory bowel disease, metabolic disorders, and neurodegenerative problems *(Zhu et al., 2021)*. These findings are crucial for translating preclinical research into effective human treatments, offering a foundation for the development of targeted probiotic therapies in clinical settings. Beyond Alzheimer's and Parkinson's disease, probiotics have demonstrated beneficial effects in various other neurological and psychological disorders in animal models:

Stress and anxiety

Probiotic administration has been shown to alleviate symptoms of stress and anxiety, potentially through modulation of the hypothalamic-pituitary-adrenal (HPA) axis.

Depression

Certain probiotic strains have antidepressant-like effects in animal models, possibly by altering gut microbiota composition and enhancing the production of serotonin and other neurotransmitters.

Autism spectrum disorder (ASD)

Probiotics may improve behavioral symptoms and gastrointestinal issues in ASD models, suggesting a link between gut health and neurodevelopmental disorders.

Limitations and Challenges

Variability in probiotic strains

The effects of probiotics are highly strain-specific. Different strains of the same species can have varying impacts on health, making it challenging to generalize findings across different probiotics. This variability necessitates precise identification and characterization of effective strains for specific conditions.

Dose and duration of treatment

Determining the optimal dose and duration of probiotic treatment is another significant challenge. The effective dose can vary widely depending on the strain and the condition being treated. Moreover, the long-term safety and efficacy of prolonged probiotic use require further investigation.

Study design and methodological concerns

Animal probiotic studies frequently confront methodological difficulties, such as limited sample numbers, a lack of established techniques, and heterogeneity in experimental circumstances. These issues can result in uneven outcomes and impede the translation of findings into human trials. Furthermore, the intricacy of the gut microbiota and its interactions with diverse host variables make probiotic effects difficult to understand.

While animal studies provide promising evidence for the potential role of probiotics in treating neurodegenerative diseases, several challenges need to be addressed to fully understand their efficacy and applicability in humans. Further research with standardized methodologies and well-designed clinical trials is essential to validate these findings and develop effective probiotic-based therapies.

Prebiotics in Neurodegenerative Diseases

By specifically promoting the development and activity of one or a small number of bacteria in the colon, prebiotics—a kind of indigestible dietary ingredient—benefit the host and enhance its health. Prebiotics provide nourishment for these good bacteria, which promotes a healthy gut microbiome, in contrast to probiotics, which are live bacteria (Fekete *et al.*, 2024).

Mechanisms of Action

- *Promoting Beneficial Bacteria*

The growth of good bacteria like Lactobacilli and Bifidobacteria is accelerated by them. In order to lower the risk of infections and preserve gut health, these bacteria have the ability to outcompete dangerous germs.

- *Metabolic Products*

Short-chain fatty acids (SCFAs) are created by the gut microbiota when prebiotics are fermented. Examples include acetate, propionate and butyrate. These SCFAs may have an impact on brain health and function since they may cross the blood-brain barrier and have systemic anti-inflammatory properties.

Animal Studies Models of Alzheimer's Disease Using Prebiotics

Animal studies have shown that prebiotics can ameliorate symptoms of Alzheimer's disease (AD). For instance, certain prebiotics have been found to reduce amyloid plaque accumulation and neuroinflammation in mouse models of AD. These effects are likely mediated by the increased production of SCFAs and the modulation of gut microbiota composition, leading to reduced systemic and neural inflammation *(Hambali et al., 2021)*.

Animal Studies Models of Parkinson's Disease Using Prebiotics

In Parkinson's disease (PD) models, prebiotics have demonstrated potential benefits by improving motor functions and reducing neurodegeneration. The underlying mechanisms may include enhanced gut barrier function, reduction in gut-derived endotoxins, and a decrease in systemic inflammation, all contributing to neuroprotection *(Pathak & Sriram, 2023)*.

Animal Studies Models of Others Using Prebiotics

Other animal studies have explored the effects of prebiotics on different neurodegenerative conditions. These studies generally support the notion that modulating the gut microbiota through prebiotics can influence brain health, potentially offering a non-invasive therapeutic strategy for various neurodegenerative diseases *(Tegegne & Kebede, 2022)*.

Limitations and Challenges

Specificity of Prebiotic Compounds

Not all prebiotics are equally effective, and their impact can vary significantly depending on their chemical structure and the specific composition of the host's gut microbiota. Identifying the most effective prebiotic compounds for specific neurodegenerative conditions remains a significant challenge *(Higgins et al., 2019)*.

Variability in Gut Microbiota Response

The response to prebiotics can be highly individual, influenced by factors such as diet, genetics, and existing microbiota composition. This variability complicates the translation of findings from animal models to human applications, as the efficacy of a given prebiotic may differ widely among individuals *(Hughes et al., 2019)*.

Study Design and Methodological Concerns

Many animal studies on prebiotics and neurodegenerative diseases suffer from methodological limitations, such as small sample sizes, short duration, and lack of standardization in prebiotic dosing and administration. Additionally, the majority of these studies are preclinical, necessitating cautious interpretation of the results and highlighting the need for well-designed clinical trials to validate these findings in humans *(Shahbazi et al., 2020)*.

Prebiotics hold promise as a potential therapeutic strategy for neurodegenerative diseases by modulating the gut-brain axis. However, the translation of preclinical findings to clinical practice faces significant hurdles, including the specificity of prebiotic compounds, individual variability in gut microbiota response, and methodological challenges in study design. Future research should focus on identifying the most effective prebiotics, understanding their mechanisms of action, and conducting robust clinical trials to establish their efficacy and safety in human populations *(Moher et al., 2015)*.

Synbiotics in Neurodegenerative Diseases

Combinations of probiotics and prebiotics that cooperate to help the host are known as synbiotics. Probiotics are living microorganisms that enhance the health of the host when taken in sufficient amounts. Non-digestible dietary ingredients known as prebiotics help the body by specifically promoting the development and/or activity of good bacteria in the digestive tract. Synbiotics stimulate the synthesis and metabolism of specific health-promoting bacteria, which improves the implantation and survival of live microbial food supplements in the gastrointestinal system *(Głowacka et al., 2024)*.

Mechanisms of Action

The mechanisms through which synbiotics exert their beneficial effects involve multiple pathways as shown in figure 2.

- *Synergistic Effects*

The combination of probiotics and prebiotics promotes the development and activity of helpful bacteria more efficiently than either alone.

- *Gut Microbiota Modulation*

By reducing the quantity of dangerous bacteria and increasing the number of beneficial bacteria, synbiotics assist to balance the gut microbiota.

- *Barrier Function Enhancement*

Synbiotics strengthen the intestinal barrier, reducing permeability and protecting against pathogenic bacteria.

- *Anti-inflammatory Effects*

Synbiotics can modulate the immune response, reducing inflammation which is crucial in neurodegenerative diseases.

- *Metabolite Production*

Beneficial byproducts of probiotics include short-chain fatty acids (SCFAs), which have neuroprotective and systemic anti-inflammatory properties.

Animal Studies Models of Alzheimer's Disease Using Synbiotics

Animal research is critical in furthering our understanding of Alzheimer's disease (AD) and identifying viable therapeutics. Synbiotics, which mix probiotics and prebiotics, are emerging as a viable treatment method.



Figure 2: Mechanisms Linking Gut Microbiota to Neuroprotection and Gut Health

These studies utilize animal models to explore how synbiotics can modulate gut microbiota, reduce neuroinflammation, and improve cognitive function. Investigating the effects of synbiotics in animal models of AD provides valuable insights into their mechanisms of action and potential benefits, paving the way for future clinical applications and innovative strategies to combat this debilitating neurodegenerative disorder *(de Oliveira et al., 2021)*.

Improvement in Cognitive Function

Studies have shown that synbiotics can improve cognitive functions in animal models of Alzheimer's disease. For example, mice treated with synbiotics showed improved performance in memory and learning tasks.

Reduction in Amyloid Plaque Deposition

The accumulation of amyloid plaques, a hallmark of Alzheimer's disease, has been linked to a decrease in the use of synbiotics.

Anti-inflammatory Effects

Synbiotics have demonstrated the ability to reduce neuroinflammation in Alzheimer's models, which is critical since inflammation is a key component of Alzheimer's disease progression.

Animal Studies Models of Parkinson's Disease Using Synbiotics

Animal study models are pivotal in understanding the pathophysiology of Parkinson's disease (PD) and exploring novel therapeutic strategies. Recent research has shifted its attention to the gut-brain axis, showing the potential of synbiotics (probiotic-prebiotic combos) in altering gut microbiota to improve neurological health. Using synbiotics in animal models of PD offers a promising avenue for investigating their neuroprotective effects, mechanisms of action, and therapeutic efficacy. This approach aims to pave the way for innovative treatments that could mitigate the progression of PD by targeting the gut microbiome, thus providing a holistic strategy for disease management *(Andreozi et al., 2024)*.

Motor Function Improvement

In animal models of Parkinson's disease, synbiotics have been shown to improve motor functions, which are severely affected in this condition.

Neuroprotective Effects

Synbiotics have exhibited neuroprotective effects by preserving dopaminergic neurons in the substantia nigra, the loss of which is a hallmark of Parkinson's disease.

Reduction in Oxidative Stress

Synbiotics have been shown in studies to lower oxidative stress indicators in the brain, which play an important role in Parkinson's disease etiology.

Animal Studies Models of Others Using Synbiotics

Animal studies have become critical in understanding the synergistic effects of synbiotics (probiotics and prebiotics) on health and illness. These models enable researchers to investigate the complex interplay between gut bacteria and host physiology in a controlled setting. Synbiotics have shown promise in enhancing gut health, boosting immune function, and mitigating various diseases in animal subjects. By elucidating the mechanisms through which synbiotics exert their benefits, animal studies provide crucial insights that pave the way for potential clinical applications in humans, thereby advancing the field of microbiome-based therapeutics *(Petrella et al., 2021)*.

Huntington's Disease Models

In models of Huntington's disease, synbiotics have shown potential in reducing neuronal degeneration and improving motor functions.

Multiple Sclerosis Models

Synbiotics have demonstrated beneficial effects in reducing neuroinflammation and demyelination in animal models of multiple sclerosis.

General Neuroprotective Effects

Various studies across different neurodegenerative disease models have consistently shown that synbiotics can exert anti-inflammatory, antioxidant, and neuroprotective effects, highlighting their broad therapeutic potential *(Huang et al., 2017).*

Limitations and Challenges

Formulation and Combination of Synbiotics

- *Specific Strains and Fibers*

Identifying the optimal combinations of probiotic strains and prebiotic fibers is challenging due to the vast number of potential combinations and the individual variations in gut microbiota.

- *Stability and Viability*

Ensuring the stability and viability of probiotics through processing, storage, and gastrointestinal passage is critical and challenging.

Dose and Duration of Treatment

- *Optimal Dosing*

Determining the effective dose that provides benefits without adverse effects is complex and varies among individuals and disease states.

- *Treatment Duration*

The appropriate duration of synbiotic treatment for sustained benefits in neurodegenerative diseases remains unclear.

Study Design and Methodological Concerns

- *Standardization*

There is a lack of standardization in study designs, including variations in synbiotic formulations, doses, and treatment durations, making it difficult to compare results across studies.

- *Reproducibility*

Ensuring reproducibility of results is a significant challenge due to differences in animal models, experimental conditions, and methodologies.

- *Human Relevance*

Translating findings from animal studies to human clinical trials involves significant challenges, including differences in physiology, disease progression, and microbiota composition. Synbiotics show promising potential in the prevention and management of neurodegenerative diseases through various mechanisms, as evidenced by animal studies. However, significant challenges and limitations must be addressed to translate these findings into effective human therapies.

Mechanistic Insights

Effects of Probiotics, Prebiotics, and Synbiotics

Utilizing probiotics, prebiotics, and synbiotics can significantly alter the composition of the gut microbiota. Together, probiotics—live beneficial bacteria—and prebiotics—dietary components that are indigestible but promote the development of beneficial bacteria—can enhance gut health *(Del Toro-Barbosa et al., 2020).*

- *Probiotics*

Certain strains have been demonstrated to increase gut barrier function and restore microbial balance, including Lactobacillus and Bifidobacterium. Probiotics may result in a decrease in dangerous pathogens and an increase in helpful microorganisms, according to studies.

- *Prebiotics*

Beneficial bacteria are fed by substances like fructooligosaccharides (FOS) and inulin, which encourage their development and activity. These prebiotics have the ability to boost the synthesis of short-chain fatty acids (SCFAs), which are essential for gut health.

- *Synbiotics*

Combining probiotics and prebiotics can have an enhanced effect on gut microbiota composition. For instance, a combination of *Lactobacillus rhamnosus* and inulin has shown improved outcomes in maintaining gut integrity and microbial balance *(Ale & Binetti, 2021)*.

Impact on Neuroinflammation and Neuroprotection

The gut microbiota has emerged as a critical player in neuroinflammation and neuroprotection, profoundly influencing brain health and disease. Recent research reveals that gut microbes can modulate the immune system, produce neuroactive compounds, and affect the integrity of the blood-brain barrier. These interactions are crucial in the context of neurodegenerative diseases, where chronic neuroinflammation is a hallmark. Probiotics, prebiotics, and synbiotics show promise in modulating gut microbiota composition, thereby potentially reducing neuroinflammation and enhancing neuroprotection *(Naomi et al., 2022)*. An understanding of these processes highlights the critical function of the gut-brain axis in neurohealth and opens up new treatment possibilities for disorders like Parkinson's and Alzheimer's diseases. The gut microbiota has a significant impact on the gut-brain axis, a two-way communication channel between the gut and the brain.

- *Neuroinflammation*

Alterations in gut microbiota composition can modulate neuroinflammatory responses. Probiotics like *Lactobacillus* and *Bifidobacterium* strains have been found to reduce the levels of pro-inflammatory cytokines in the CNS, thus potentially mitigating neuroinflammation.

- *Neuroprotection*

Probiotics, prebiotics, and gut microbiota can affect the synthesis of neuroprotective substances. To improve brain health, SCFAs, for example, can penetrate the blood-brain barrier and have neuroprotective qualities.

Metabolic Products and Neurodegeneration

The interplay between metabolic products and neurodegeneration is a burgeoning area of research, revealing critical insights into how metabolic dysfunction contributes to neurological decline. Metabolites produced by gut microbiota, such as short-chain fatty acids and neurotransmitter precursors, significantly influence brain health and cognitive function. Disruptions in these metabolic processes are increasingly linked to the pathogenesis of neurodegenerative diseases like Alzheimer's and Parkinson's. Understanding the intricate relationships between metabolic products and neuronal health holds promise for developing novel therapeutic strategies aimed at mitigating the progression of neurodegenerative disorders and enhancing overall brain health *(Cheng et al., 2021)*.

Short-Chain Fatty Acids (SCFAs)

SCFAs, such as acetate, propionate, and butyrate, are produced by the fermentation of dietary fibers by gut microbiota. SCFAs are critical for maintaining the integrity of the blood-brain barrier, regulating neuroinflammation, and supporting neuronal health. Butyrate, in particular, has been shown to have anti-inflammatory and neuroprotective effects, which may help in mitigating neurodegenerative diseases like Alzheimer's and Parkinson's.

SCFAs can influence gene expression and neurotransmitter production through epigenetic mechanisms, such as histone deacetylase inhibition, which promotes anti-inflammatory gene expression and neuronal survival.

Other Relevant Metabolites

In addition to probiotics, prebiotics, and synbiotics, other metabolites produced by gut microbiota play crucial roles in human health. Short-chain fatty acids (SCFAs), bile acids, and neurotransmitters like serotonin and dopamine are among these key metabolites. SCFAs, such as acetate, propionate, and butyrate, contribute to gut health, immune function, and metabolic regulation *(Moher et al., 2015)*. The bile acids aid in digestion and also modulate metabolic processes. Neurotransmitters produced by gut microbes can influence brain function and behavior. Understanding these metabolites' mechanisms and effects is essential for developing comprehensive therapeutic strategies that leverage the full potential of the gut microbiome. Besides SCFAs, other metabolites produced by gut microbiota can impact neurodegeneration *(Khan et al., 2020)*.

Tryptophan Metabolites

The metabolism of tryptophan by gut bacteria leads to the production of serotonin and other neuroactive compounds. Dysregulation of tryptophan metabolism has been linked to mood disorders and cognitive decline.

Bile Acids

Gut microbiota also modify bile acids, which can influence brain function. Secondary bile acids have been implicated in neurodegenerative processes through their effects on the gut-brain axis and neuroinflammatory pathways.

Immune System Modulation

The immune system serves as the body's frontline defense against pathogens and foreign invaders, playing a critical role in maintaining overall health and well-being. Immune system modulation, the process of regulating immune responses, has emerged as a promising approach in various fields of medicine *(Bosi et al., 2020)*. By fine-tuning immune activity, researchers and clinicians aim to address a wide range of conditions, from autoimmune diseases to cancer. This paradigm shift towards immune modulation reflects a deeper understanding of the intricate interplay between immune cells, cytokines, and regulatory mechanisms. As research progresses, novel therapeutic strategies are being developed to harness the power of immune modulation in promoting health and combating disease *(Finamore et al., 2019)*.

Interaction with the Central Nervous System (CNS)

The intricate interplay between the gut microbiota and the Central Nervous System (CNS) represents a burgeoning area of scientific inquiry with profound implications for human health. Emerging research has elucidated the bidirectional communication pathways, known as the gut-brain axis, through which the gut microbiota influences CNS function and vice versa. This dynamic relationship extends beyond mere digestion, exerting significant influence on mood regulation, cognitive function, and even neurological disorders. Understanding the mechanisms underlying this interaction holds immense promise for innovative therapeutic interventions targeting neurological conditions and enhancing overall well-being *(Guigoz et al., 2008)*. The immune system plays a crucial role in maintaining CNS health and function, and gut microbiota are key modulators of immune responses.

Microglia Activation

Gut microbiota can influence the activation of microglia, the resident immune cells in the CNS. Balanced gut microbiota helps maintain microglia in a homeostatic state, preventing chronic neuroinflammation.

Cytokine Production

Gut bacteria modulate the production of cytokines, which can cross the blood-brain barrier and influence brain function. Probiotics have been shown to enhance the production of anti-inflammatory cytokines while reducing pro-inflammatory cytokines, thereby supporting CNS health.

Role in Reducing Inflammation and Oxidative Stress

The intricate interplay between gut microbiota and human health is increasingly recognized as a pivotal factor in maintaining physiological balance and mitigating disease risk. In recent years, research has illuminated the profound impact of gut microbiota on modulating inflammation and oxidative stress, two key processes implicated in the pathogenesis of numerous chronic conditions *(Sarkar et al., 2016)*. Understanding the role of gut microbiota in regulating these fundamental pathways holds immense therapeutic potential, offering novel avenues for intervention in inflammatory and oxidative stress-related disorders. This paper explores the emerging evidence elucidating the mechanisms through which gut microbiota contribute to reducing inflammation and oxidative stress, paving the way for innovative therapeutic strategies. Inflammation and oxidative stress are key drivers of neurodegenerative diseases *(Turnbaugh et al., 2006)*.

Antioxidant Production

Certain gut bacteria produce metabolites with antioxidant properties, which can reduce oxidative stress in the CNS. For example, the production of glutathione, a potent antioxidant, can be enhanced by a healthy gut microbiota.

- Modulating gut microbiota composition through diet, probiotics, or prebiotics can reduce systemic inflammation, which in turn reduces neuroinflammation. This modulation can involve downregulating pathways like NF-κB, which is a major regulator of inflammatory responses.

The gut microbiota plays a pivotal role in influencing neurodegenerative processes through various mechanisms, including modulation of microbial composition, production of metabolic products, and interaction with the immune system. Understanding these mechanisms can lead to novel therapeutic strategies for neurodegenerative diseases, emphasizing the importance of maintaining a healthy gut microbiota for overall brain health.

Clinical Implications and Future Directions

Personalized nutrition, or precision nutrition, tailors dietary recommendations to individual characteristics like genetic makeup, microbiome composition, and lifestyle factors. This approach shows promise in managing chronic diseases such as diabetes, obesity, and cardiovascular conditions by optimizing nutrient intake, enhancing metabolic health, and reducing disease risk. For instance, specific probiotic strains can support gut health in individuals with microbiota imbalances, while dietary fibers can promote beneficial microbial growth. Integrating personalized nutrition into existing treatment protocols for conditions like inflammatory bowel disease (IBD) and cancer can improve outcomes and quality of life by mitigating symptoms and side effects.

Despite its potential, larger and more rigorous clinical trials are needed to establish the efficacy and safety of personalized nutrition and microbiome-based therapies. Current studies suffer from limitations like small sample sizes and heterogeneous methodologies. Future research should prioritize large-scale, randomized controlled trials to validate specific interventions across diverse populations and assess long-term impacts on health outcomes.

Exploring novel probiotic, prebiotic, and synbiotic formulations presents another crucial research avenue. By investigating new strains and compounds and their synergistic effects, researchers can develop more targeted and effective therapeutic options. Innovations in delivery mechanisms, such as encapsulation technologies, can enhance the viability and efficacy of these formulations, paving the way for more personalized treatments.

The implementation of personalized nutrition and microbiome-based therapies raises safety and regulatory concerns. A thorough evaluation of new formulations is necessary to ensure their safety and efficacy, particularly regarding potential interactions with medications. Regulatory frameworks must evolve to keep pace with these innovations and ensure equitable access to personalized nutrition services while addressing ethical considerations like genetic data privacy.

Patient adherence and acceptability are essential for the success of personalized nutrition interventions. Lifestyle adjustments required by personalized dietary plans can be challenging for patients. Strategies like clear guidance, digital support tools, and patient involvement in treatment planning can improve adherence. Understanding and addressing barriers to adherence, such as cost and complexity, are crucial for maximizing the therapeutic potential of these approaches.

Conclusion

The significant potential of probiotics, prebiotics, and synbiotics in personalized nutrition and microbiome-based therapies. Key findings underscore the effectiveness of these interventions in optimizing gut health and mitigating disease risk across various chronic conditions. Furthermore, insights into the underlying mechanisms and clinical applications have provided valuable knowledge for healthcare providers and researchers. The role of gut microbiota in neurodegenerative disease management emerges as a crucial area of investigation. The implications of microbiome modulation on neurological health are profound, suggesting a promising avenue for intervention in conditions like Alzheimer's and Parkinson's diseases. The future outlook holds great promise, with personalized nutrition and microbiome-based therapies offering potential breakthroughs in disease prevention and management.

However, a need for continued research and innovation in the field. Larger and more rigorous clinical trials are necessary to establish the efficacy and safety of these interventions across diverse populations. Moreover, the exploration of novel probiotic, prebiotic, and synbiotic formulations is essential for maximizing therapeutic benefits and addressing individualized patient needs. The convergence of personalized nutrition, microbiome research, and neurodegenerative disease management presents an exciting frontier in healthcare. By harnessing the power of gut microbiota, we have the opportunity to revolutionize disease prevention and treatment strategies. Continued collaboration between researchers, healthcare professionals, and regulatory agencies is imperative to realize the full potential of these innovative approaches in improving patient outcomes and public health.

References

1. Elandia, P. P. (2022). Global and regional spending on dementia care from 2000–2019 and expected future health spending scenarios from 2020–2050: An economic modelling exercise. *EClinicalMedicine, 45*, 101337. https://doi.org/10.1016/j.eclinm.2022.101337
2. Tian, Z., Ji, X., & Liu, J. (2022). Neuroinflammation in vascular cognitive impairment and dementia: Current evidence, advances, and prospects. *International Journal of Molecular Sciences, 23*(11), 6224. https://doi.org/10.3390/ijms23116224
3. Kwon, H. S., & Koh, S.-H. (2020). Neuroinflammation in neurodegenerative disorders: The roles of microglia and astrocytes. *Translational Neurodegeneration, 9*(1), Article 42. https://doi.org/10.1186/s40035-020-00221-2
4. Laver, K., Dyer, S., Whitehead, C., *et al.* (2016). Interventions to delay functional decline in people with dementia: A systematic review of systematic reviews. *BMJ Open, 6*(e010767). https://doi.org/10.1136/bmjopen-2015-010767
5. Aizawa, E., Tsuji, H., Asahara, T., *et al.* (2016). Possible association of

Bifidobacterium and *Lactobacillus* in the gut microbiota of patients with major depressive disorder. *Journal of Affective Disorders, 202*, 254–257.
6. Huang, R., Wang, K., & Hu, J. (2016). Effect of probiotics on depression: A systematic review and meta-analysis of randomized controlled trials. *Nutrients, 8*(1–2).
7. Hyde, C., Peters, J., Bond, M., *et al.* (2013). Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: Systematic review and economic model. *Age and Ageing, 42*(1), 14–20. https://doi.org/10.1093/ageing/afs195
8. Rao, A. K., Chou, A., Bursley, B., *et al.* (2014). Systematic review of the effects of exercise on activities of daily living in people with Alzheimer's disease. *American Journal of Occupational Therapy, 68*(1), 50–56. https://doi.org/10.5014/ajot.2014.010330
9. Burns, A., & Iliffe, S. (2009). Dementia. BMJ, 338, 405–409. https://doi.org/10.1136/bmj.b75
10. World Health Organization (WHO). (n.d.). Alzheimer disease and other dementias. Retrieved November 15, 2019, from https://www.who.int/medicines/areas/priority_medicines/BP6_11Alzheimer.pdf Zhu, X., Li, B., Lou, P., Dai, T., Chen, Y., Zhuge, A., Yuan, Y., & Li, L. (2021). The relationship between the gut microbiome and neurodegenerative diseases. *Neuroscience Bulletin, 37*(10), 1510–1522. https://doi.org/10.1007/s12264-021-00730-8
11. Hambali, A., Kumar, J., Hashim, N. F. M., Maniam, S., Mehat, M. Z., Cheema, M. S., Mustapha, M., Adenan, M. I., Stanslas, J., & Hamid, H. A. (2021). Hypoxia-induced neuroinflammation in Alzheimer's disease: Potential neuroprotective effects of *Centella asiatica*. *Frontiers in Physiology, 12*, 712317. https://doi.org/10.3389/fphys.2021.712317
12. Fekete, M., Lehoczki, A., Major, D., Fazekas-Pongor, V., Csípő, T., Tarantini, S., Csizmadia, Z., & Varga, J. T. (2024). Exploring the influence of gut–brain axis modulation on cognitive health: A comprehensive review of prebiotics, probiotics, and symbiotics. *Nutrients, 16*(6), 789. https://doi.org/10.3390/nu16060789
13. de Oliveira, J., Kucharska, E., Garcez, M. L., Rodrigues, M. S., Quevedo, J., Moreno-Gonzalez, I., & Budni, J. (2021). Inflammatory cascade in Alzheimer's disease pathogenesis: A review of experimental findings. *Cells, 10*(10), 2581. https://doi.org/10.3390/cells10102581
14. Pathak, D., & Sriram, K. (2023). Molecular mechanisms underlying neuroinflammation elicited by occupational injuries and toxicants. *International Journal of Molecular Sciences, 24*(3), 2272. https://doi.org/10.3390/ijms24032272
15. Tegegne, B. A., & Kebede, B. (2022). Probiotics, their prophylactic and therapeutic applications in human health development: A review of the literature. *Heliyon, 8*(e09725). https://doi.org/10.1016/j.heliyon.2022.e09725
16. Shahbazi, R., Yasavoli-Sharahi, H., Alsadi, N., Ismail, N., & Matar, C. (2020). Probiotics in treatment of viral respiratory infections and neuroinflammatory disorders. *Molecules, 25*(21), 4891. https://doi.org/10.3390/molecules25214891
17. Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews, 4*(1), 1. https://doi.org/10.1186/2046-4053-4-1
18. Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., & Welch, V. A. (Eds.). (2019). *Cochrane Handbook for Systematic Reviews of Interventions* (Version 6.0). Cochrane. Available from https://training.cochrane.org/handbook
19. Głowacka, P., Oszajca, K., Pudlarz, A., Szemraj, J., & Witusik-Perkowska, M. (2024). Postbiotics as molecules targeting cellular events of aging brain—the role in pathogenesis, prophylaxis, and treatment of neurodegenerative diseases. *Nutrients, 16*(14), 2244. https://doi.org/10.3390/nu16142244
20. Hughes, R. L., Kable, M. E., Marco, M., & Keim, N. L. (2019). The role of the gut microbiome in predicting response to diet and the development of precision nutrition models. Part II: Results. *Advances in Nutrition, 10*(6), 979–998. https://doi.org/10.1093/advances/nmz049
21. Andreozi, V., Cuoco, S., Balestrieri, M., Fierro, F., Ferrara, N., Erro, R., Di Filippo, M., Barbella, G., Memoli, M. C., Silvestri, A., Squillante, M., Guglielmetti, S., Barone, P., Iovino, P., & Pellecchia, M. T. (2024). Synbiotic supplementation may globally improve non-motor symptoms in patients with stable Parkinson's disease: Results from an open-label single-arm study. *Scientific Reports, 14*, Article 23095. https://doi.org/10.1038/s41598-024-23095-0
22. Petrella, C., Strimpakos, G., Torcinaro, A., Middei, S., Ricci, V., Gargari, G., Mora, D., De Santa, F., & Farioli-Vecchioli, S. (2021). Proneurogenic and neuroprotective effect of a multi-strain probiotic mixture in a mouse model of acute inflammation: Involvement of the gut-brain axis. *Pharmacological Research, 172,* 105795. https://doi.org/10.1016/j.phrs.2021.105795
23. Huang, R., Ning, H., Yang, L., Jia, C., Yang, F., & Xu, G. (2017). Efficacy of probiotics on anxiety: A meta-analysis of randomized controlled trials. *Neuropsychiatry, 7*(6), 862–871. https://doi.org/10.4172/Neuropsychiatry.1000291
24. Del Toro-Barbosa, M., Hurtado-Romero, A., Garcia-Amezquita, L. E., & García-Cayuela, T. (2020). Psychobiotics: Mechanisms of action, evaluation methods, and effectiveness in applications with food products. *Nutrients, 12*(12), 3896. https://doi.org/10.3390/nu12123896
25. Ale, C. E., & Binetti, A. G. (2021). Role of probiotics, prebiotics, and synbiotics in the elderly: Insights into their applications. *Frontiers in Microbiology, 12*, 631254. https://doi.org/10.3389/fmicb.2021.631254
26. Naomi, R., Embong, H., Othman, F., Ghazi, H. F., Maruthey, N., & Bahari, H. (2022). Probiotics for Alzheimer's disease: A systematic review. *Nutrients, 14*(1), 20. https://doi.org/10.3390/nu14010020
27. Cheng, Y.-J., Lin, C.-H., & Lane, H.-Y. (2021). Involvement of cholinergic, adrenergic, and glutamatergic network modulation with cognitive dysfunction in Alzheimer's disease. *International Journal of Molecular Sciences, 22*(5), 2283. https://doi.org/10.3390/ijms22052283
28. Moher, D., Shamseer, L., Clarke, M., ... & PRISMA-P Group. (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews, 4*, 1. https://doi.org/10.1186/2046-4053-4-1
29. Khan, S., Barve, K. H., & Kumar, M. S. (2020). Recent advancements in pathogenesis, diagnostics, and treatment of Alzheimer's disease. *Current Neuropharmacology, 18*(10), 1106–1125. https://doi.org/10.2174/1570159X18666200528142429
30. Bosi, A., Banfi, D., Bistoletti, M., Giaroni, C., & Baj, A. (2020). Tryptophan metabolites along the microbiota-gut-brain axis: An interkingdom communication system influencing the gut in health and disease. *International Journal of Tryptophan Research, 13*, 1178646920928984. https://doi.org/10.1177/1178646920928984
31. Finamore, A., Roselli, M., Donini, L. M., Brasili, D. E., Rami, R., Carnevali, P., ... & Mengheri, E. (2019). Supplementation with *Bifidobacterium longum* Bar33 and *Lactobacillus helveticus* Bar13 mixture improves immunity in elderly humans (over 75 years) and aged mice. *Nutrition, 63–64*, 184–192. https://doi.org/10.1016/j.nut.2019.02.005
32. Guigoz, Y., Doré, J., & Schiffrin, E. J. (2008). The inflammatory status of old age can be nurtured from the intestinal environment. *Current Opinion in Clinical Nutrition and Metabolic Care, 11*(1), 13–20. https://doi.org/10.1097/MCO.0b013e3282f2bfdf
33. Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., ... & Gordon, J. I. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature, 444*(7122), 1027–1031.
34. Sarkar, A., Lehto, S. M., Harty, S., ... & Cryan, J. F. (2016). Psychobiotics and the manipulation of bacteria-gut-brain signals. *Trends in Neurosciences, 39*(11), 763–781.

HOW TO CITE THIS ARTICLE: Yadav, A.S., Shukla, D., Yadav, A., Singh, V.K., Kori, Y.S. Exploring the role of Probiotics, Prebiotics, and Symbiotics in the management of neurodegenerative disease. J. of Drug Disc. and Health Sci. 2025;2(1):37-46. **DOI:** 10.21590/jddhs.02.01.06